A Double-Blind Trial of Penbutolol: A New Beta-Receptor Blocking Agent in the Treatment of Angina Pectoris
- 1 November 1976
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 4 (6) , 410-417
- https://doi.org/10.1177/030006057600400606
Abstract
A double-blind placebo controlled study of angina pectoris with Penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for Penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the Penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.This publication has 21 references indexed in Scilit:
- Efficacy of beta adrenergic blockade in coronary heart disease: Propranolol in angina pectorisClinical Pharmacology & Therapeutics, 1975
- An evaluation of sotalol, a β-blocking agent, in patients with angina pectorisPublished by Oxford University Press (OUP) ,1974
- The medical treatment of angina pectoris VI. Propranolol as an antianginal drugAmerican Heart Journal, 1972
- Practolol in Treatment of Angina Pectoris. A Double-blind TrialBMJ, 1970
- The effect of propranolol on exercise-induced ischemic S-T segment depressionThe American Journal of Cardiology, 1969
- On resting the human heartThe American Journal of Medicine, 1968
- Relation of Heart Rate and Systolic Blood Pressure to the Onset of Pain in Angina PectorisCirculation, 1967
- Use of Propranolol in Angina PectorisBMJ, 1965
- Double-blind Trail to Propranolol (Inderal) in Angina PectorisBMJ, 1965
- COUNCIL ON PHARMACY AND CHEMISTRYJAMA, 1955